Contaminate Removal for Laboratory Pharmaceutical Synthesis

描述（由申请人提供）：Compact Membrane Systems, Inc.提议修订1 R43 GM084478-01A1，题为“实验室药物合成的污染物去除”，以响应通知no - od -09-058，“NIH宣布竞争性修订申请的恢复法案资金可用性”，在该修订申请中，我们提议去除污染物，如未反应的反应物。用纳滤膜分离技术对废催化剂和废有机溶剂的副产物进行了研究。这是原方案范围的两个维度变化：1)膜的操作模式与原方案不同；2)分离的范围远远超出了从溶剂中去除水和氧污染物。最初的项目专注于开发小型和低成本的膜系统，用于去除有机合成溶剂中的氧气和水污染物。大多数有机药物化学合成都是在有机溶剂中完成的。有机溶剂中的氧和/或水污染物会破坏许多有机反应物和有机金属试剂和催化剂。因此，氧和水的去除对有机合成的成功至关重要。不幸的是，氧气和水都是无处不在的，必须付出巨大的努力来去除氧气和水，并继续将它们排除在系统之外。此修订也是对NIH RFP PA-09-100题为“能源效率和可再生能源系统技术研究与开发”的响应。通过使用压力驱动的纳滤与热驱动的分离，如蒸馏回收制药废溶剂，我们也直接响应NIH的节能工艺RFP。该计划将增加额外的资源，包括必要的设备，以及新员工，包括有经验的和刚毕业的大学毕业生。紧凑膜系统公司拥有众多的工业和大学合作伙伴，他们对这项技术表现出浓厚的兴趣。这些合作伙伴将在第一阶段项目和随后的第二阶段活动和商业化中提供帮助。

DESCRIPTION (provided by applicant): Compact Membrane Systems, Inc. is proposing a revision to grant 1 R43 GM084478-01A1 entitled "Contaminate Removal for Laboratory Pharmaceutical Synthesis" in response to notice NOT-OD-09-058, "NIH Announces the Availability of Recovery Act Funds for Competitive Revision Applications" In this revision application, we are proposing to remove contaminants such as un-reacted reactants, spent catalysts and by-products from spent organic solvents by the membrane separation technique of nanofiltration. This is a two dimensional change in the scope of the original program: 1) the mode of operation of the membrane is different from the original program 2) scope of separations is well beyond removing water and oxygen contaminants from solvents. The original program was focused on developing small and low cost membrane based system for removal of oxygen and water contaminants from organic synthesis solvents. Most organic pharmaceutical chemical syntheses are done in organic solvents. Oxygen and/or water contaminants in organic solvents will destroy many organic reactants and organometallic reagents and catalysts. As such, the removal of oxygen and water are critical to successful organic synthesis. Unfortunately both oxygen and water are ubiquitous and significant effort must be introduced to both remove oxygen and water and continue to keep them out of the system. This revision is also responsive to NIH RFP PA-09-100 entitled "Energy Efficiency and Renewable Energy System Technology Research & Development". By using a pressure-driven nanofiltration versus a thermal- driven separation such as distillation for recovery of pharmaceutical spent solvents, we also are directly responsive to this NIH's RFP for energy efficient processes. Additional resources will be added to the program including necessary equipment to carry out the effort as well as new hires including both experienced and new college graduates. Compact Membrane Systems has numerous industrial and university partners which have shown a strong interest in this technology. These partners will be helpful in the Phase I program and subsequent Phase II activity and commercialization. PUBLIC HEALTH RELEVANCE: This project will develop a membrane product and process to not only remove dissolved oxygen and water from reaction solvents and reactants but also be expanded to include un-reacted chemicals, spent catalysts and by-products from spent organic solvents. The membrane system is in principle universal and very low cost. This development will represent an application of CMS membrane technology that has considerable significance to production costs related to pharmaceutical manufacturing.